Cystectomy Clinical Trials

Clinical trials related to Cystectomy Procedure

A Phase I/II Clinical Study Evaluating the Safety, Efficacy, Tolerability, and Pharmacokinetics of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This is a multicenter, open-label, Phase I/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10566 in patients with high-risk non-muscle-invasive bladder cancer who are ineligible for or refuse radical cystectomy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Men or women aged greater than or equal to (≥) 18 years.

• Signed informed consent form.

• Histologically confirmed non-muscle-invasive bladder urothelial carcinoma (i.e., transitional cell carcinoma). Mixed tumor types predominantly consisting of urothelial carcinoma are eligible. Patients diagnosed with neuroendocrine, micropapillary, signet-ring cell, plasmacytoid, or sarcomatoid features are excluded.

• Patients with non-muscle-invasive bladder cancer (NMIBC) who have undergone prior transurethral resection of bladder tumor (TURBT) and who refuse or are ineligible for radical cystectomy, and meet one of the following two populations:

‣ Patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy after prior TURBT, and who refuse or are ineligible for radical cystectomy. BCG unresponsive is defined as occurrence of any one of the following in NMIBC patients after adequate BCG therapy (at least 5 full dose inductions and at least 2 maintenance instillations of BCG):

• Persistent or recurrent CIS within 12 months after adequate BCG therapy, with or without recurrence of high-grade Ta or T1 tumors;

∙ Recurrence of high-grade Ta/T1 tumors within 6 months after adequate BCG therapy;

∙ Recurrence of high-grade T1 tumors at the first assessment during maintenance therapy after BCG induction.

⁃ Patients who have not received BCG therapy after prior TURBT, including the following three scenarios:

• NMIBC patients who failed intravesical chemotherapy, and who have not received BCG.

∙ HR-NMIBC patients who have not received BCG therapy after TURBT.

∙ HR-NMIBC patients who received prior BCG therapy but discontinued treatment for more than 3 years before enrollment.

• Participants must have undergone TURBT within 12 weeks prior to signing informed consent and meet the following criteria:

‣ For papillary lesions (Ta and T1 stages): complete resection of all visible papillary lesions, with negative urine cytology (including atypical findings).

⁃ For patients with CIS: residual unresectable CIS lesions are permitted.

• Sufficient bone marrow reserve and adequate hepatic/renal function.

• Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.

Locations
Other Locations
China
Peking University First Hospital
RECRUITING
Beijing
Nanjing Drum Tower Hospital
RECRUITING
Nanjing
Contact Information
Primary
Zhisong HE, M.D(Doctor of Medicine)
wyj7074@sohu.com
(+86) 13910688432
Backup
Hongqian GUO, M.D(Doctor of Medicine)
gymwpi@126.com
(+86) 025 83106666
Time Frame
Start Date: 2026-08-05
Estimated Completion Date: 2029-04-30
Participants
Target number of participants: 180
Treatments
Experimental: Arm 1:Bacillus Calmette-Guerin (BCG)-unresponsive participants with carcinoma in situ.
HS-10566 is placed into the bladder through a urinary placement catheter in participants with CIS, with or without papillary disease, on Day 1 and will be dosed Q4W for up to the first 24 weeks (6 months), then every 12 weeks through Week 96 (Year 2).
Experimental: Arm 2: BCG-unresponsive participants with high-risk papillary-only disease
HS-10566 is placed into the bladder through a urinary placement catheter in participants with papillary disease only, on Day 1 and will be dosed Q4W for up to the first 24 weeks (6 months), then every 12 weeks through Week 96 (Year 2).
Experimental: Arm 3: BCG-naïve participants with high-risk disease
HS-10566 is placed into the bladder through a urinary placement catheter in participants with BCG-naïve high-risk disease, on Day 1 and will be dosed Q4W for up to the first 24 weeks (6 months), then every 12 weeks through Week 96 (Year 2).
Related Therapeutic Areas
Sponsors
Leads: Jiangsu Hansoh Pharmaceutical Co., Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials